Last Updated: September 25, 2022

   
     


 
Featured Articles

American Academy of HIV Medicine Launches Long-Acting Agent Resource Center

American Academy of HIV Medicine | August 22, 2022

Long-acting Agent Resource Center website

HIV LAA | August 2022

2022 HIV Drug Chart

POZ | June 27, 2022

12 Surprisingly Interesting Facts About Making Medicines And The Pharma Industry

Sintered Filter | May 10, 2022

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

HIV.gov | January 20, 2022

Updates in the Pipeline of HIV Therapy

Infectious Disease Special Edition | January 14, 2022

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention

NIH | December 21, 2021

FDA Approves APRETUDE (cabotegravir) for HIV-1 Pre-Exposure Prophylaxis

FDA | December 20, 2021

TAG’s 2021 Pipeline Report: The Latest in HIV and HCV R&D

Treatment Action Group | October 2021

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

AIDSinfo | August 16, 2021

At Last, Generic HIV Prevention Drugs Promise Savings And Access—But Also Reveal Precarious Financing

Health Affairs | May 20, 2021

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

aidsinfo | February 10, 2021

   
News Updates

GlaxoSmithKline's long-acting HIV drug nabs FDA priority review as a preventative option 

Fierce Pharma | September 28, 2022

Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study 

J Int AIDS Soc. 2022 Sep;25(9):e26006. doi: 10.1002/jia2.26006.

Dolutegravir Offers Superior HIV Suppression in Pregnant Women

Contagion Live | September 14, 2022

Dolutegravir Compared With Other Regimens for HIV in Pregnancy 

Consumer Health News - HealthDay | September 1, 2022

Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States 

N Engl J Med. 2022 Sep 1;387(9):799-809. doi: 10.1056/NEJMoa2200600.

European Commission Approves Once Every 6 Month Supplemental HIV-Treatment

HIV/HCV Watch | August 2022

Antibiotics Increase Risk for Inflammatory Bowel Disease in Older Adults 

Infectious Disease Advisor | August 16, 2022

Antibiotics Increase Risk for Inflammatory Bowel Disease in Older Adults 

Infectious Disease Advisor | August 16, 2022

Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study

BMC Infectious Diseases - BioMed Central | August 15, 2022

Quick Take: Equitable Access to New HIV Treatment And Prevention Options Is Needed Across Payers

O’Neill Institute | August 2022

Quick Take: New Options for HIV Treatment And Prevention Are Here

O’Neill Institute | August 2022

Fostemavir Improves Outcomes for Treatment-Resistant HIV Patients

Contagion Live | July 30, 2022

Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir

Gilead | July 27, 2022

Gilead doubles down on HIV prevention, treatment amid Covid setbacks and awaiting FDA decision on long-acting candidate

Endpoints News | July 21, 2022

On-Demand PrEP Works as Well as Daily Pills

POZ | July 12, 2022

Long-acting Treatment and Prevention of HIV Are Here

Medscape | July 8, 2022

GSK's ViiV, under threat from Gilead-Merck collab, eyes 'ultra-long-acting' HIV drugs with ??Halozyme deal

Fierce Pharma | june 22, 2022

Substantial weight gain as dolutegravir is rolled out in Africa

Aidsmap | June 21, 2022

ViiV Healthcare looks to make long-acting HIV prevention shot accessible in low 

Endpoints News | May 27, 2022

NHS England is considering off-label use of Descovy PrEP

Aidsmap | May 17, 2022

FDA Lifts Clinical Hold on Long-Acting Lenacapavir

POZ | May 17, 2022

Gilead's HIV prospect lenacapavir escapes FDA hold

Fierce Pharma | May 16, 2022

FDA approves label update to ViiV's long-acting HIV treatment

Outsourcing Pharma | April 26, 2022

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

The Lancet | April 20, 2022

Risk for Incident Liver Damage in Patients With HIV on Antiretroviral Therapy 

Infectious Disease Advisor | April 12, 2022

Counterfeit HIV Drugs: Justice Department Opens Investigation

Medscape | April 11, 2022

Provider Survey: Prior Authorizations Harm Patients

CANN | April 4, 2022

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

The Lancet | April 1, 2022

FDA Approves Triumeq, ViiV Healthcare's Daily Treatment for Children Living With HIV 

Contagion Live | March 30, 2022

ViiV Healthcare announces US FDA approval of Cabenuva for virologically suppressed adolescents living with HIV who are 12 years of age or older and weigh at least 35 kg

MarketScreener | March 30, 2022

Uncertain Future for 2 Long-Acting HIV Therapies

Infectious Disease Special Edition | March 30, 2022

FDA makes oral lead-in optional for long-acting injectable HIV regimen

Healio | March 24, 2022

Bottlenecks are slowing switch to GSK's long-acting HIV injectable Cabenuva: clinician

Fierce Pharma | March 8, 2022

FDA rejects Gilead's HIV drug lenacapavir over glass vial concerns

Healio | March 2, 2022

Evaluation of Sociodemographic Factors and Prevalence of Oral Lesions in People Living with HIV from Cacoal, Rondônia, Amazon Region of Brazil

Int J Environ Res Public Health. 2022 Feb 24;19(5):2614. doi: 10.3390/ijerph19052614.

Long-acting HIV-1 Capsid Inhibitor Sustained Efficacy in Phase 2/3 Study

Precision Vaccinations | February 19, 2022

Cabenuva Approved for 2 Month Injections; Insurers Remain a Barrier to Access

Co-infection Watch | February 2022

HIV: Dual Therapy With Twice-Yearly Injections on the Horizon

Medscape | February 18, 2022

Antiviral Efficacy, Safety, Tolerability of a Novel HIV-1 Maturation Inhibitor (GSK'254) 

Infectious Disease Advisor | January 27, 2022

Multidrug-Resistant HIV With Limited Treatment Options: No Longer an Unmet Need?

Clinical Care Options

Antimicrobial resistance causes more deaths than HIV and malaria

News Medical | January 22, 2022

HIV Provider Organization to Launch New Web Resource on Long-Acting Agents

American Academy of HIV Medicine | January 6, 2022

Dolutegravir-Based Treatment More Effective in Children Living With HIV

Contagion Live | January 6, 2022

Outcomes of Dolutegravir Treatment in Patients With HIV Infection Who Failed Antiretroviral Therapy 

Infectious Disease Advisor | January 5, 2022

   

 
         
  2019 Archives 2020 Archives 2021 Archives